Recce Pharmaceuticals

Corporate Governance

Why Invest

News and Media

Announcements

Titillium Web

Recce's Entitlement Offer is now live! Visit the page for instructions on how to participate

Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has received A$801,604 as part of a non-dilutive advance from Radium Capital for the company’s Research and Development (R&D) tax incentive.

This advance payment from Radium Capital represents an accountant-verified proportion of its March-May FY23 R&D applicable expenditure.

The non-dilutive funds come in addition to the recently reported A$973,144, seeing A$3,682,787 of future R&D credit-backed funds received and redeployed this financial year to date.

Recce CEO James Graham said: “We welcome the latest R&D rebate advance of A$801,604 to support our ongoing clinical progress and achieve our operational goals.”

The Australian Government’s 43.5% Research & Development Tax Incentive rebate is typically reserved for Australian-based R&D only. However, it also can capture 43.5% of R&D applicable activities overseas, as reflected in this rebate.

Recce is developing a new class of synthetic anti-infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens.

The company’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives, including:

RECCE 327 is an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms;

RECCE 435 is an orally administered therapy for bacterial infections; and

Recce’s anti-infective pipeline seeks to exploit the unique capabilities of its technologies targeting synergistic, unmet medical needs.

Read the full article here: https://www.proactiveinvestors.com.au/companies/news/1020438/recce-pharmaceuticals-receives-a-801-604-in-r-d-rebate-advance-1020438.html?viewSource=TwitterAU

Recce Pharmaceuticals receives A$801,604 in R&D rebate advance